Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company specializing in novel therapeutics and drug delivery systems, announced that its representatives will attend the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. The forum provides a platform for experts in nasal drug development to discuss innovations in this field, and Silo's participation underscores its commitment to advancing SPC-15, its intranasal formulation designed for the treatment of post-traumatic stress disorder (PTSD).
CEO Eric Weisblum emphasized the strategic importance of the forum for Silo, noting that it offers an opportunity to engage with key opinion leaders and industry peers as the company progresses SPC-15's novel nose-to-brain delivery approach. This method aims to enhance targeted drug delivery to the central nervous system, potentially offering a more effective and rapid treatment option for PTSD, a condition that affects millions worldwide and has seen limited therapeutic advancements.
The company's participation is backed by promising preclinical data. Silo reported that SPC-15's formulation and delivery device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent with long-term stability findings, indicating the product's robustness and readiness for further development. These results are critical as they support the feasibility of commercial-scale production and regulatory approval.
The implications of Silo's progress are significant for the biopharmaceutical industry, particularly in the realm of CNS disorders. Traditional oral or injectable medications often face challenges such as poor bioavailability or systemic side effects. The nose-to-brain pathway bypasses the blood-brain barrier, potentially allowing for lower doses and reduced adverse effects. If successful, SPC-15 could set a precedent for other nasal therapeutics targeting neurological conditions, including fibromyalgia and chronic pain, which Silo is also exploring with its SP-26 candidate.
For investors and stakeholders, Silo's engagement at the IPAC-RS forum signals active development and networking within the industry. The company's diversified pipeline, including preclinical assets for Alzheimer's disease and multiple sclerosis, positions it as a multifaceted player in addressing underserved medical needs. However, as with all developmental-stage biopharmaceuticals, there are inherent risks and uncertainties, including regulatory hurdles and the need for additional clinical trials.
The news of Silo's participation was disseminated through MissionIR, a specialized communications platform that enhances visibility for companies within the investment community. MissionIR is part of the Dynamic Brand Portfolio @ IBN, which offers a range of services including press release distribution and social media amplification. For more information about Silo Pharma, interested parties can visit the company's website or its newsroom at https://ibn.fm/SILO. The full press release is available at https://ibn.fm/Dy4qf.
As Silo prepares to showcase its SPC-15 data at the upcoming forum, the company continues to navigate the complex landscape of drug development, driven by a mission to bring innovative therapies to patients with unmet needs.
